Ecofuryl, capsules 100 mg 30 pcs

Pharmacotherapeutic group: Antimicrobial agent, nitrofuran

ATX code: A07AXX03

Pharmacological properties

.Pharmacodynamics
Nifuroxazide is an antimicrobial agent, a nitrofuran derivative. It blocks the activity of dehydrogenases and inhibits respiratory chains, tricarboxylic acid cycle and a number of other biochemical processes in the microbial cell. It destroys microbial cell membrane and reduces production of toxins by microorganisms. Highly active against Campylobacter jejuni, Escherichia coli, Salmonella spp, Shigella spp.; Clostridium perfringens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolyticus, Staphylococcus spp.
Weakly sensitive to nifuroxazide: Citrobacter spp, Enterobacter cloacae and Proteus indologenes. Resistant to nifuroxazide: Klebsiella spp., Proteus mirabilis, Providencia spp., Pseudomonas spp. He disrupts the balance of intestinal microflora. In bacterial diarrhea restores intestinal eubiosis. In infection with enterotropic viruses prevent the development of bacterial superinfection.

Pharmacokinetics
After oral administration nifuroxazide is practically not absorbed from the digestive tract and its antibacterial effect is exclusively in the intestinal lumen. Nifuroxazide is excreted by the intestine: 20% unchanged and the rest chemically altered.

Indications

Acute bacterial diarrhea, occurring without deterioration in general condition, increase in body temperature, or intoxication.

Pharmacological effect

Pharmacotherapeutic group: antimicrobial agent, nitrofuran

ATX code: A07AX03

Pharmacological properties

Pharmacodynamics
Nifuroxazide is an antimicrobial agent derived from nitrofuran. Blocks the activity of dehydrogenases and inhibits the respiratory chain, the tricarboxylic acid cycle and a number of other biochemical processes in the microbial cell. Destroys the microbial cell membrane, reduces the production of toxins by microorganisms. Highly active against Campylobacter jejuni, Escherichia coli, Salmonella spp., Shigella spp.; Clostridium perfringens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolyticus, Staphylococcus spp.
Weakly sensitive to nifuroxazide: Citrobacter spp., Enterobacter cloacae and Proteus indologenes. Resistant to nifuroxazide: Klebsiella spp., Proteus mirabilis, Providencia spp., Pseudomonas spp. Does not disturb the balance of intestinal microflora. In case of bacterial diarrhea, it restores intestinal eubiosis. When infected with enterotropic viruses, they prevent the development of bacterial superinfection.

Pharmacokinetics
After oral administration, nifuroxazide is practically not absorbed from the digestive tract, and exerts its antibacterial effect exclusively in the intestinal lumen. Nifuroxazide is excreted by the intestines: 20% unchanged, and the rest chemically modified.

Special instructions

When treating diarrhea, rehydration therapy must be carried out simultaneously with nifuroxazide therapy. In case of bacterial diarrhea with signs of systemic damage (deterioration of general condition, increased body temperature, symptoms of intoxication or infection), you should consult a doctor to decide on the use of systemic antibacterial drugs. If symptoms of hypersensitivity appear (shortness of breath, swelling of the face, lips, tongue, skin rash, itching), you should immediately stop taking the drug. Drinking alcohol during nifuroxazide therapy is prohibited. The excipients contain sucrose in a dosage of 24 mg for a 100 mg capsule and 48 mg for a capsule
200 mg. Thus, a single dose of sucrose when taking 100 and 200 mg capsules will be 24 mg and 48 mg, respectively. The daily dose of sucrose when taking 100 and 200 mg capsules will be 96 mg and 192 mg, respectively.

With caution
Liver diseases, alcoholism, traumatic brain injury, brain diseases, lactation period, childhood.

Impact on the ability to drive vehicles and machinery
The drug does not affect the ability to drive vehicles and machinery.

Active ingredient

Nifuroxazide

Composition

Composition per capsule:

Active ingredient:

nifuroxazide 100.0 mg 200.0 mg

Excipients:

lactitol 300.0 mg 300.0 mg
microcrystalline cellulose 102 23.0 mg 58.0 mg
potato starch 9.0 mg 18.0 mg
magnesium stearate 4.0 mg 6.0 mg
sucrose until the contents of the capsule weigh
460.0 mg 630.0 mg

Hard gelatin capsules:

gelatin up to 100% up to 100%
quinoline yellow dye 0.9197% 0.3497%
sunset dye 0.0044% 0.0116%
titanium dioxide 1.3333% 0.8742%

Pregnancy

In animal studies, no teratogenic effect was detected.
However, as a precaution, taking nifuroxazide during pregnancy is not recommended. During the lactation period, it is possible to continue breastfeeding in case of a short course of treatment with the drug. You should consult your doctor.

Contraindications

Hypersensitivity to nifuroxazide, nitrofuran derivatives or any excipients of the drug.

Children up to 3 years old.

Pregnancy.

Congenital intolerance to fructose, galactose, galactosemia,
glucose-galactose malabsorption.

Side Effects

Allergic reactions (skin rash, urticaria, Quincke’s edema, anaphylactic shock). If any of the side effects listed in the instructions get worse or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Concomitant use with drugs that cause the development of disulfiram-like reactions or drugs that inhibit the function of the central nervous system is not recommended. If you are taking other medications (including over-the-counter medications), consult your doctor before using Ecofuril®.

Overdose

Overdose symptoms are not known. Treatment is symptomatic.

Storage conditions

Store in a place protected from moisture and light at a temperature not exceeding 25 °C.
Keep out of the reach of children.

Shelf life

5 years. Do not use after expiration date.

Manufacturer

ABVA RUS, Russia